Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies

Yamada, Daisaku; Kobayashi, Shogo; Doki, Yuichiro et al.

International Journal of Clinical Oncology, 2025

Number of Access:266（2025-07-19 21:04 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/101411

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
IntJClinOncol pdf None 641 KB 13 2025.06.03  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies
Creator
NRID
1000060571396 1000060571396
ORCID
0000-0002-6702-3800 0000-0002-6702-3800
researchmap permalink
dyamada79222 dyamada79222
Scopus Author ID
37008067700 37008067700
CreatorName
Yamada, Daisaku
NRID
1000030452436 1000030452436
CreatorName
Kobayashi, Shogo
NRID
1000020291445 1000020291445
researchmap permalink
ydoki3251 ydoki3251
Scopus Author ID
7006390687 7006390687
CreatorName
Doki, Yuichiro
NRID
1000090542118 1000090542118
researchmap permalink
abcdabcdabcd abcdabcdabcd
Scopus Author ID
7101627772 7101627772
CreatorName
Eguchi, Hidetoshi
Subject
Biliary tract cancer
Cancer genome testing
Target therapy
Description
The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-025-02761-x.
Abstract
Biliary tract cancers (BTCs) are classified on the basis of their anatomical origin, and the feasibility of surgical resection depends on the tumor location and extent of progression. However, for unresectable BTCs, systemic therapy has been uniformly applied. Gemcitabine and cisplatin (GC) therapy and GC-based therapies were established as the first-line standard BTC treatment. However, no highly effective second-line therapy has been established, and the prognosis remains poor, highlighting the need for further therapeutic advancements. Meanwhile, the era of precision medicine has expanded the use of genetic testing, leading to the identification of actionable molecular targets in BTC. Several targeted therapies, including FGFR inhibitors and IDH1 inhibitors, have been developed, offering new second-line treatment options and the potential for first-line use in appropriate cases. Notably, the frequency of these genetic alterations varies depending on the tumor location, demonstrating the molecular heterogeneity of BTC. Therefore, it has been recognized that a tailored treatment approach for each BTC patient may be more effective than uniform systemic therapy. Consequently, although routine genetic testing before initiating systemic treatment is currently limited by the medical environment (e.g., cost, accessibility, regional differences), it is recommended in ESMO guideline and might be increasingly advocated. However, BTC harbors a wide range of genetic alterations, and numerous targeted therapies are being developed accordingly. This review provides an overview of the reported genetic alterations in BTC, the frequencies of these alterations, and the corresponding targeted therapies, emphasizing the evolving role of precision medicine in BTC treatment.
Publisher
Springer
Source Title
International Journal of Clinical Oncology
Date of Issued
2025-04-25
Language
English
Handle URL
https://hdl.handle.net/11094/101411
PISSN
13419625
eISSN
14377772
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1007/s10147-025-02761-x
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article